Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector

Exclusion Criteria

• •1. History of allergic reactions attributed to Arsenic Trioxide
• •2. Experiencing uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• •3. Pregnant
• •4. HIV-positive patients and taking combination antiretroviral therapy.
• •5. History of having circulating malignant cells if the patient has lymphoma or myeloma
• •6. Impaired cardiac function or clinically significant cardiac diseases, including any of the following: history of long QT syndrome; mean QTc (corrected QT interval) \> 500 msec on screening EKG; history of clinically manifest ischemic heart disease including myocardial infarction; stable or unstable angina, coronary arteriography or cardiac stress testing/imaging with findings consistent with coronary occlusion or infarction \< 6 months prior to study start; history of heart failure or left ventricular (LV) dysfunction (LVEF \< 45%) by MUGA or ECHO; clinically significant EKG abnormalities including one or more of the following: left bundle branch block (LBBB), right bundle branch block (RBBB) with left anterior hemiblock (LAHB). ST segment elevations or depressions \> lmm, or 2nd (Mobitz 11) or 3rd degree AV block; history or presence of atrial fibrillation, atrial flutter or ventricular arrhythmias including ventricular tachycardia or Torsades de Pointes; other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen); clinically significant resting bradycardia (\< 50 beats per minute); obligate use of a cardiac pacemaker.